An aspirin a day? Clinical utility of aspirin therapy for the primary prevention of cardiovascular disease

References

• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–e528.
   PubMed Web of Science ®Google Scholar
• Craven LL. Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg. 1950;4:95.
   PubMedGoogle Scholar
• Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458–2473.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–2381.
   PubMed Web of Science ®Google Scholar
• Luepker RV, Steffen LM, Duval S, et al. population trends in aspirin use for cardiovascular disease prevention 1980–2009: the Minnesota heart survey. J Am Heart Assoc. 2015;4.
   Web of Science ®Google Scholar
• Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012–2015. Prev Med Rep. 2017;5:183–186.
   PubMedGoogle Scholar
• Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. CHEST. 2012;141:e637S–e668S.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103–S123.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019:e000–e000.
   Google Scholar
• Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164:836–845.
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1988;318:262–264
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509–1518.
   PubMed Web of Science ®Google Scholar
• ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–1539.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–1046.
   PubMed Web of Science ®Google Scholar
• U.S. Preventive Services Task Force. Aspirin prophylaxis for cardiovascular disease. U.S. preventive services task force. Am Fam Physician. 1989;40:117–120.
   PubMed Web of Science ®Google Scholar
• Manson JE, Stampfer MJ, Colditz GA, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266:521–527.
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force. Aspirin prophylaxis for the primary prevention of myocardial infarction. In: Guide to clinical preventive services. Report of the US preventive services task force [Internet]. 2nd edition. Baltimore (MD). Williams & Wilkins; 1996. Available from: https://www.ncbi.nlm.nih.gov/books/NBK15424/
   Google Scholar
• Hennekens Charles H, Dyken Mark L, Valentin F. Aspirin as a Therapeutic Agent in Cardiovascular Disease. Circulation. 1997;96:2751–2753.
   PubMedGoogle Scholar
• Pearson TA, Blaire SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation. 2002;106:388–391.
   PubMed Web of Science ®Google Scholar
• U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157–160.
   PubMed Web of Science ®Google Scholar
• Hernández-Díaz S, Rodríguez LAG. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol. 2002;55:157–163.
   PubMed Web of Science ®Google Scholar
• Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–313.
   PubMed Web of Science ®Google Scholar
• US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. preventive services task force recommendation statement. Ann Intern Med. 2009;150:396–404.
   PubMed Web of Science ®Google Scholar
• Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975;56:624–632.
   PubMed Web of Science ®Google Scholar
• Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation. 2011;123:768–778.
   PubMed Web of Science ®Google Scholar
• Hogg K, Weitz JI. Blood coagulation and anticoagulant, fibrinolytic, and antiplatelet drugs. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman’s: the Pharmacological basis of therapeutics, 13e. New York, NY: McGraw-Hill; 2018.
   Google Scholar
• Dippel DWJ, Van Kooten F, Leebeek FWG, et al. What is the lowest dose of aspirin for maximum suppression of in vivo thromboxane production after a transient ischemic attack or ischemic stroke? Cerebrovasc Dis. 2004;17:296–302.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392:387–399.
   PubMed Web of Science ®Google Scholar
• Hoftiezer JW, Silvoso GR, Burks M, et al. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man. Lancet. 1980;2:609–612.
   PubMed Web of Science ®Google Scholar
• Takada M, Fukumoto K, Shibakawa M. Concomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugs. J Clin Pharm Ther. 2004;29:183–187.
   PubMed Web of Science ®Google Scholar
• Hirata Y, Kataoka H, Shimura T, et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol. 2011;46:803–809.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Grosser T, Dong J-F, et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2017;69:603–612.
   PubMed Web of Science ®Google Scholar
• Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 1996;348:1413–1416.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;61:e78–e140.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Imfeld S, Markham J, et al. The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders. Thromb Res. 2015;135:217–225.
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MMC, Eikenboom JCJ, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167:1593–1599.
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195–198.
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702–1708.
   PubMed Web of Science ®Google Scholar
• Whitlock EP, Burda BU, Williams SB, et al. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2016;164:826.
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health study. N Engl J Med. 1989;321:129–135.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510–2520.
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
   PubMed Web of Science ®Google Scholar
• Fowkes FGR, Price JF, Stewart MCW, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841–848.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension optimal treatment. J Hypertens. 2000;18:629–642.
   PubMed Web of Science ®Google Scholar
• Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ. 2000;321:13–17.
   PubMedGoogle Scholar
• Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–1304.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–2141.
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379:1519–1528.
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379:1499–1508.
   PubMed Web of Science ®Google Scholar
• García LR, Martín-Pérez M, Hennekens CH, et al. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS One. 2016;11:e0160046–e0160046.
   PubMed Web of Science ®Google Scholar
• Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988;296:313–316.
   PubMed Web of Science ®Google Scholar
• The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351:233–241.
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT study group. Lancet. 1998;351:1755–1762.
   PubMed Web of Science ®Google Scholar
• de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative group of the primary prevention project. Lancet. 2001;357:89–95.
   PubMed Web of Science ®Google Scholar
• Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. preventive services task force. Ann Intern Med. 2016;164:804.
   PubMed Web of Science ®Google Scholar
• ASCVD Risk Estimator [Internet]. Washington (DC): American College of Cardiology; [ cited 2019 May 17]. Available from: http://tools.acc.org/ASCVD-Risk-Estimator-Plus/
   Google Scholar
• Khan SU, Ul Abideen Asad Z, Khan MU, et al. Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: an updated systematic review and meta-analysis. Eur J Prev Cardiol. 2019;1–8.
   Google Scholar
• Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321:277–287.
   PubMed Web of Science ®Google Scholar
• Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110:2361–2367.
   PubMed Web of Science ®Google Scholar
• Sundström J, Hedberg J, Thuresson M, et al. Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study. Circulation. 2017;136:1183–1192.
   PubMed Web of Science ®Google Scholar
• Vial JH, McLeod LJ, Roberts MS. Rebound elevation in urinary thromboxane B2 and 6-keto-PGF1 alpha excretion after aspirin withdrawal. Adv Prostaglandin Thromboxane Leukot Res. 1991;21A:157–160.
   PubMedGoogle Scholar
• Doutremepuich C, Aguejouf O, Desplat V, et al. Paradoxical thrombotic effects of aspirin: experimental study on 1000 animals. Cardiovasc Hematol Disord Drug Targets. 2010;10:103–110.
   PubMedGoogle Scholar
• Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129:S49–73.
   PubMed Web of Science ®Google Scholar
• Lanas A, Polo-Tomás M, Casado-Arroyo R. The aspirin cardiovascular/gastrointestinal risk calculator–a tool to aid clinicians in practice. Aliment Pharmacol Ther. 2013;37:738–748.
   PubMed Web of Science ®Google Scholar
• Lahaye S, Regpala S, Lacombe S, et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost. 2014;111:465–473.
   PubMed Web of Science ®Google Scholar
• Song Y, Liu X, Zhu X, et al. Increasing trend of diabetes combined with hypertension or hypercholesterolemia: NHANES data analysis 1999–2012. Sci Rep. 2016;6:36093.
   PubMed Web of Science ®Google Scholar